INBIOGEN Co., Ltd. (KRX:101140)
South Korea
· Delayed Price · Currency is KRW 12,630
-920 (-6.79%)
At close: Apr 30, 2025
INBIOGEN Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 7,041 | 6,241 | 10,420 | 10,481 | 10,218 | Upgrade
|
| Other Revenue | -0 | - | - | - | 0 | Upgrade
|
| Revenue | 7,041 | 6,241 | 10,420 | 10,481 | 10,218 | Upgrade
|
| Revenue Growth (YoY) | 12.82% | -40.11% | -0.58% | 2.57% | 4.31% | Upgrade
|
| Cost of Revenue | 6,413 | 4,933 | 8,447 | 8,652 | 9,446 | Upgrade
|
| Gross Profit | 628.51 | 1,308 | 1,972 | 1,829 | 771.48 | Upgrade
|
| Selling, General & Admin | 5,518 | 5,727 | 6,643 | 8,124 | 5,490 | Upgrade
|
| Research & Development | 21.89 | 8.19 | 3.67 | 24.6 | - | Upgrade
|
| Other Operating Expenses | 59.69 | 577.86 | 124.04 | 158.74 | 96.62 | Upgrade
|
| Operating Expenses | 6,715 | 7,471 | 7,942 | 9,975 | 6,032 | Upgrade
|
| Operating Income | -6,087 | -6,164 | -5,969 | -8,146 | -5,261 | Upgrade
|
| Interest Expense | -51.35 | -262.15 | -3,686 | -3,830 | -6,233 | Upgrade
|
| Interest & Investment Income | 924.91 | 1,289 | 1,823 | 1,839 | 1,004 | Upgrade
|
| Earnings From Equity Investments | 21,538 | -32,457 | 42,777 | -5,062 | -19,726 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | -13.77 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 959.14 | 10,750 | 16,875 | 10,421 | -28,031 | Upgrade
|
| EBT Excluding Unusual Items | 17,284 | -26,844 | 51,819 | -4,792 | -58,247 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.04 | 39,032 | -178,976 | 115,995 | 14,314 | Upgrade
|
| Gain (Loss) on Sale of Assets | -168.16 | -64.79 | - | -138.43 | -46.1 | Upgrade
|
| Asset Writedown | -992.37 | - | - | - | -76.67 | Upgrade
|
| Other Unusual Items | - | -263.58 | -6,745 | - | -1,162 | Upgrade
|
| Pretax Income | 16,122 | 11,859 | -133,902 | 111,064 | -45,218 | Upgrade
|
| Income Tax Expense | - | - | -16,953 | 16,939 | -140.81 | Upgrade
|
| Earnings From Continuing Operations | 16,122 | 11,859 | -116,949 | 94,125 | -45,078 | Upgrade
|
| Earnings From Discontinued Operations | - | -514.7 | -268.78 | - | - | Upgrade
|
| Net Income | 16,122 | 11,344 | -117,218 | 94,125 | -45,078 | Upgrade
|
| Net Income to Common | 16,122 | 11,344 | -117,218 | 94,125 | -45,078 | Upgrade
|
| Net Income Growth | 42.12% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | - | 9 | 4 | 3 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | - | 9 | 4 | 3 | 2 | Upgrade
|
| Shares Change (YoY) | - | 134.70% | 21.34% | 44.57% | -6.45% | Upgrade
|
| EPS (Basic) | - | 1333.01 | -32327.53 | 35054.16 | -21809.01 | Upgrade
|
| EPS (Diluted) | - | 1333.01 | -32327.53 | 31498.90 | -21809.01 | Upgrade
|
| Free Cash Flow | -117.41 | -1,077 | -11,636 | -9,430 | -8,461 | Upgrade
|
| Free Cash Flow Per Share | - | -126.51 | -3209.03 | -3155.62 | -4093.39 | Upgrade
|
| Gross Margin | 8.93% | 20.95% | 18.93% | 17.45% | 7.55% | Upgrade
|
| Operating Margin | -86.45% | -98.77% | -57.29% | -77.73% | -51.49% | Upgrade
|
| Profit Margin | 228.98% | 181.77% | -1124.99% | 898.07% | -441.17% | Upgrade
|
| Free Cash Flow Margin | -1.67% | -17.25% | -111.67% | -89.97% | -82.80% | Upgrade
|
| EBITDA | -5,030 | -4,940 | -4,531 | -7,029 | -4,817 | Upgrade
|
| EBITDA Margin | -71.43% | -79.15% | -43.49% | -67.07% | -47.15% | Upgrade
|
| D&A For EBITDA | 1,057 | 1,224 | 1,438 | 1,117 | 443.42 | Upgrade
|
| EBIT | -6,087 | -6,164 | -5,969 | -8,146 | -5,261 | Upgrade
|
| EBIT Margin | -86.45% | -98.77% | -57.29% | -77.73% | -51.49% | Upgrade
|
| Effective Tax Rate | - | - | - | 15.25% | - | Upgrade
|
| Advertising Expenses | 26.66 | 31.43 | 65.86 | 66.51 | 37.79 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.